Fibronectins: Multifunctional Modular Glycoproteins

RICHARD O. HYNES and KENNETH M. YAMADA
Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139; and the Membrane Biochemistry Section, Laboratory of Molecular
Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205

Fibronectins are large glycoproteins that have been implicated in a wide variety of cellular properties, particularly those involving the interactions of cells with extracellular materials. These properties include cell adhesion, morphology, cytoskeletal organization, migration, differentiation, oncogenic transformation, phagocytosis, and hemostasis. During the past several years, investigations in many laboratories have analyzed the expression, functions, and structure of fibronectins. These studies have revealed that fibronectins have a complex molecular structure consisting of multiple specific binding sites, and the complex biological phenomena in which fibronectins participate can now be considered in terms of this structure.

In this brief article we will review the current understanding of the structure and properties of fibronectins. Because a number of comprehensive reviews on various aspects of fibronectins have been published (1-13), we shall focus on overall concepts, recent developments and promising future research directions in this rapidly expanding field.

Sources of Fibronectins

In vivo, fibronectins are found in body fluids (300 μg/ml in plasma, lesser amounts in other fluids), soft connective tissue matrices, and most basement membranes. Fibronectins are synthesized by a wide variety of cells in vitro (Table I). Fibroblasts and endothelial cells are major producers, but many other cell types, including some epithelial cells, synthesize fibronectin at lower levels. There are at least two types of fibronectin, termed plasma and cellular fibronectins, although there may well be multiple forms of cellular fibronectin. Cellular and plasma fibronectins, although distinguishable, are very similar in structure and properties (see below). One major source of plasma fibronectin appears to be hepatocytes (14, 15)[1] although endothelial cells (16-18) and macrophages (19-22) could also contribute, given their close association with the bloodstream.

---

[1] Wherever reference 15 appears, it refers to a paper by Tamkun, J. W., and R. O. Hynes, submitted for publication.

Properties of Fibronectins

The basic properties of fibronectins are listed in Table II. The molecule is asymmetric and consists of two similar or identical subunits of molecular weight 220,000 ± 20,000 daltons held together by disulfide-bonding near their carboxyl termini. Biophysical measurements indicate that, although the molecule as a whole is flexible, it contains compact globular domains (23, 24). Electron microscopic results confirm the idea that the molecule is extended and flexible (25-27), although the globular domains have not yet been observed by this technique.

One important characteristic of fibronectins is that they are capable of interacting specifically with a wide variety of other macromolecules. Table III lists the various interactions, some of which have been studied in more detail than others. The best-established interactions, for which evidence exists both for their occurrence in vivo and for their specificity in vitro, are the interactions with gelatin and collagens, fibrin, factor XIIIa transglutaminase, heparin, and proteoglycans. In addition, it is clear that fibronectins interact with many cells; however, the molecular basis for this interaction remains unclear and is one of the major unanswered questions concerning fibronectins. The binding sites on fibronectins involved in many of these interactions have been identified and isolated, as will be discussed in a later section.

Although plasma fibronectin exists as a soluble protein, the typical appearance of cellular fibronectin is as a fibrillar extracellular matrix. The fibrils containing fibronectin can also contain collagens (28, 29) and proteoglycans (30-32). It is possible that interactions between fibronectin and other matrix molecules are important in the formation of these fibrils. The detailed molecular interactions involved in the formation of extracellular matrices and basement membranes are another area of active research.

FUNCTIONS OF FIBRONECTINS

Table IV summarizes the cellular properties in which fibronectins have been implicated. The most thoroughly studied, and perhaps most basic, function of fibronectins is in the adhesion to solid substrates. Numerous studies have reported that fibronectins promote the adhesion and/or spreading of cells on a variety of materials including plastic, collagen, gelatin, and fibrin (33-36). Cells that synthesize their own fibronectin do

TABLE I
Fibronectin Synthesis In Vitro*

Cell type	Comments
Fibroblasts	Often decreased after oncogenic transformation
Endothelial cells	High rate of synthesis, large proportion secreted in vitro
Chondrocytes	Amount correlates inversely with differentiation
Myoblasts & myotubes	Quantity appears to differ according to source of cells; transformed cells have less; myotubes often have less than myoblasts
Macrophages	All or most is secreted
Hepatocytes	All or most is secreted plasma fibronectin
Amniotic cells	Amniotic FN is more heavily glycosylated
Glial cell lines	Glial cells in vivo probably do not synthesize FN.
Intestinal epithelial cells	Small amounts only
Mammary epithelial cells	Decreased on metastatic cells
Teratocarcinomas	Changes with differentiation
Early embryonic tissues	Cells from all three germ layers have been reported to synthesize fibronectin.

* Specific references can be found in earlier reviews (see 1, 4, 11, and 13 for summary tables with references) and in the text.

TABLE II
Properties of Fibronectins*

Subunits	220,000 ± 20,000-dalton chains in disulfide-bonded dimer.
pI	5.5–6.3
Carbohydrate	5–9% asparagine-linked complex oligosaccharides.
Sulfhydryl groups	One or two in the C-terminal 30%
Disulfide bonds	~20 per subunit. Intersubunit bond(s) are very near C-terminal. N-terminal 25% is very rich in intrachain disulfides.
Secondary structure	No α helix, probably some β structure.
Tertiary structure	Asymmetric and elongated with globular domains.
High order associations	Form disulfide-bonded complexes and fibrils.

* Specific references can be found in earlier reviews (see 3, 4, and 12 for summary tables with references) and in the text.

not require exogenous fibronectin for adhesion and spreading, but many cells that produce little or none will respond to added fibronectin. Among these cells are some oncogenically transformed cells that produce reduced quantities of fibronectin as a consequence of transformation (37, 38).

Concomitant with the spreading induced by added fibronectin, cells often acquire highly ordered intracellular microfilament bundles (38, 39). Furthermore, extracellular fibrils that contain fibronectin are often observed to correspond in their arrangement with intracellular microfilament bundles (40–47). Fig. 1 shows examples of this phenomenon. These results, and others, suggest that there may be some form of physical connection between the extracellular matrix and the intracellular cytoskeleton (10). The molecular basis for this interaction is not understood as yet. However, the idea that the cytoskeleton and the extracellular matrix are part of a continuous supra-

molecular assemblage has important implications for considerations of the effects of extracellular matrices on cellular behavior.

Interestingly, oncogenic transformation causes a pleiotropic change in cellular properties including reduced adhesion, rounded morphology, and loss of cytoskeletal organization, as well as loss of fibronectin. Because all of these changes can, in some cases, be reverted by addition of fibronectin (37–39), it is possible that they reflect a common effect of the transforming agent (48). Extensive studies have shown that loss of fibronectin is a common, though not universal, concomitant of transformation (1–13). The reasons for the loss appear to vary, and include reduced synthesis (49, 50), reduced binding (49–53), and increased rates of degradation (49, 54). Correlative studies suggest some association between loss of fibronectin and tumorigenicity in vivo (e.g., 55, 56) but exceptions have been noted (e.g., 57, 58), and preliminary studies suggest that a better correlation may exist between loss of fibronectin and acquisition of metastatic potential (59–61). Given the involvement of fibronectin in adhesion to extracellular matrices, effects on invasion and metastasis might be expected from alterations in this aspect of cellular function.

In vitro experiments have shown that fibronectin will promote cell migration in culture (62, 63) and can stimulate chemotaxis or haptotaxis (64, 65). This raises the possibility that fibronectin might promote or guide cell migration in embryos and, indeed, fibronectin has been found in association with several areas of cell migration including avian gastrula (66), neural crest (67–70), area vasculosa (68), amphibian primordial germ cells (71), and sea urchin primary mesenchyme (72, 73). Perhaps also related to an involvement in cell migration is the stimulation by fibronectin of neurite outgrowth from retinal cell aggregates (74). It should be stressed that the

TABLE III
Interactions of Fibronectins

	Selected references
Gelatin, denatured collagens, collagens I–V	*
Fibrin, fibrinogen	*
Factor XIIIa transglutaminase	*
Heparin	*
Proteoglycans	*
Cells	*
Bacteria	75, 76
Actin	127
DNA	137
Hyaluronic acid	*
Gangliosides	165, 166
Asymmetric acetylcholinesterase	167
Clq component of complement	77, 78, 79
Thrombospondin	97

* See text and reviews for specific references.

TABLE IV
Functions of Fibronectins*

Cellular adhesion
Cellular morphology and spreading
Cytoskeletal (microfilament) organization
Oncogenic transformation
Cell migration/chemotaxis or haptotaxis
Phagocytosis
Hemostasis/thrombosis
Embryonic differentiation

* Specific references for the various functions are given in the text.

FIGURE 1   Codistribution of fibronectin fibrils and actin microfilament bundles. (A and B) Double label immunofluorescence of NIL8 hamster cells arrested in low serum (cf. reference 40) A shows fibronectin stain, B shows actin staining of the same cells. Arrows mark some of the coincidences. (C and D) Immunoperoxidase staining of fibronectin in Xenopus mesentery cell cultures. C shows peroxidase staining of fibronectin. D shows a phase photograph of the same field. Actin microfilament bundles are colinear with the fibronectin (reprinted from reference 71). (E) Immunoferritin staining of fibronectin in tsSV40-hamster embryo fibroblasts at nonpermissive temperature. Figure shows an oblique section through the base of the cell with fibronectin fibril outside cell at left colinear with actin microfilament bundle inside cell at right (reprinted from reference 42). (F) Similar section of NIL8 hamster cells not stained with antibody. Figure again shows extracellular fibrils colinear with intracellular microfilament bundles (picture courtesy of Irwin Singer).

371

presence of fibronectin in areas of cell migration does not prove that it is functionally involved, even less that it is the only relevant matrix component.

A functional role for fibronectin in phagocytosis was originally suggested on the basis of in vivo results that showed that levels of plasma fibronectin correlated with the ability of an organism to clear particulate debris, especially gelatin-coated particles, from the circulation (5). It was suggested that fibronectin was acting as a "non-specific opsonin" for the reticuloendothelial system. This suggestion became even more interesting with the observation that fibronectin binds to certain bacteria (75, 76). The recently reported binding of Clq by fibronectin (77–79) might also be important in phagocytosis of antibody aggregates or fragments of cells lysed by complement. In vitro studies have shown that fibronectin will indeed promote phagocytosis of gelatin-coated beads by certain macrophages although heparin is required as a cofactor (21, 80–82). No detailed studies have yet shown fibronectin to act as an opsonin for bacteria. Thus, the in vivo relevance of the "opsonic" activity of fibronectin remains unclear and is under active investigation. One interpretation of fibronectin-stimulated endocytosis is that it is simply a specialized form of cell spreading on a substratum with a small rather than an infinite radius of curvature.

Another possible role of plasma fibronectin is in hemostasis and thrombosis. During coagulation, fibronectin is crosslinked to fibrin by factor XIIIa transglutaminase (83, 84). Furthermore, platelets contain intracellular fibronectin (85, 86), possibly in their α-granules, and release it on activation (86–88). Activated platelets will also bind exogenous plasma fibronectin (50, 88, 89). Consequently, at the site of interaction of platelets with endothelial cell basement membrane, there are three possible sources of fibronectin; plasma, basement membrane, and the platelets themselves. Because other adhesive proteins such as von Willebrands factor and thrombospondin are also present in the platelets, the basement membrane and the plasma (88, 90–94), the adhesion of platelets is likely to be complex. The exact role of fibronectin in this process remains unclear but, under certain artificial in vitro conditions, fibronectin can promote the adhesion and/or spreading of platelets (50, 95, 97). Crosslinking experiments suggest that an interaction between fibronectin and thrombospondin occurs when platelets spread on solid substrata (97). Thrombospondin has also been implicated in platelet aggregation (98, 99).

Finally, fibronectin has been implicated in the regulation of several differentiation pathways. Fibronectin has been reported both to stimulate myogenesis and to inhibit myoblast fusion (100, 101) and to inhibit chondrogenesis (102–104). The precursor cells of both the myogenic and chondrogenic lineage are fibronectin-positive, and there appears to be a loss of fibronectin during progression along these two differentiation pathways (103–108). Fibronectin has also been reported to inhibit melanogenesis and to promote adrenergic differentiation in explanted neural crest cells (109, 110). Extracellular matrices have long been thought to play important roles in development. Fibronectin has now joined collagens and proteoglycans as a candidate for a role in these processes, as have even more recently discovered glycoproteins such as laminin and chondronectin. Clearly the role of the various matrix constituents, singly and in combination, in various differentiative events will be an active area of research in the next few years.

Fibronectins therefore appear to be involved in an almost embarrassingly large array of cellular functions. How can an individual molecule perform so many functions? The following sections review our current understanding of the structure-function relationships of fibronectins.

STRUCTURE AND FUNCTIONAL DOMAINS OF FIBRONECTINS

As mentioned above, spectrophotometric and ultracentrifugation experiments indicate that cellular and plasma fibronectins are elongated molecules composed of structured domains separated by flexible, extendable regions of polypeptide chain (23, 24, 111). By electron microscopy, fibronectins are usually visualized as slender, elongated molecules with regions of apparently increased flexibility (25, 26), although they can appear more globular under certain conditions (27). Variability also exists in the hydrodynamic radius, which is known to increase or decrease, depending upon ionic strength (23). A unifying interpretation of these studies is that fibronectins are highly flexible molecules that can expand or contract depending upon the local environment.

Flexible polypeptide regions of proteins such as fibronectin tend to be particularly susceptible to attack by a variety of proteases. Proteases will cleave such regions to generate separate, structured domains of the molecule containing specific binding sites for ligands (e.g., collagen and heparin, see Table III).

There are two approaches to purifying such structural domains from fibronectin or any molecule with binding sites. In the first, specific ligands are coupled covalently to agarose beads and are poured into affinity columns. The fibronectin is allowed to bind to the column and then incubated with various proteases. Under appropriate conditions, the enzymes cleave the molecule into protease-resistant domains. After extensive washing of the column, the only regions that remain bound to the column are domains specific for binding to the specific ligand. An alternative approach is to pretreat the fibronectin with proteases, to inhibit the proteases with protease inhibitors, and to pour the entire digest over affinity columns. Specific protease-resistant domains then bind to the column, and other fragments are discarded. These two approaches have been surprisingly successul in identifying and purifying a series of protease-resistant, functional domains of fibronectin and locating these domains and other structural features on the molecule (112–132). Fig. 2 shows the current model based on these results.

Collagen-binding Domain

The first domain of fibronectin to be isolated was the collagen-binding domain. This region of the molecule is ~30–40,000 daltons in size, and can be produced after digestion of the intact molecule with chymotrypsin, subtilisin, thermolysin, or even the broad spectrum protease pronase (112, 114, 116, 117, 119, 120, 124, 125). This region binds to collagen or to gelatin affinity columns, yet cannot mediate cell interactions. Larger fragments are produced by different proteolytic conditions and allow mapping of the collagen-binding domain near to but not at the amino-terminius (112, 113, 115, 116, 118, 119, 120, 122–125, 128–131).

Cell-binding Domain

The cell-binding activity appears to require a separate region, the "cell-binding" region of fibronectin, that can be purified

FIGURE 2 A current working model for the modular structure of fibronectins. The molecules are composed of elongated subunits linked by disulfide bonds near the carboxyl terminus. Some regions are extremely sensitive to proteolysis and are depicted as extended chains (thin lines). Other regions are compact and globular and contain specific binding sites for other molecules. Two protease-resistant domains (*I* and *II*) are well-defined and readily purified. The remainder of the molecule is less well-analyzed, but appears to contain regions that are relatively sensitive to proteolysis (constrictions) and other less sensitive regions that can be isolated by virtue of their binding affinities. The locations of the different binding sites on the molecule are indicated. See text for details.

from among the fragments of the molecule that do not bind to collagen affinity columns (112, 116, 120, 125, 128, 129, 132). The cell-binding region of fibronectin can mediate the attachment and spreading of cells on simple plastic substrates, even though it is inactive in mediating the attachment of cells to collagen. A fragment of 15,000 daltons still retains a significant amount of the cell binding activity of the intact molecule, but does not bind to either collagen or heparin (132). This fragment has been isolated using a monoclonal antibody that blocks cell binding activity (132). Analyses of partial digests show that this 15-kdalton fragment and the cell-binding site lie in the central part of the molecule (116, 120, 125, 128, 129, 132).

Fibrin and Transglutaminase Interaction Sites

The binding of fibronectin to fibrin from blood may be important in the initial stages of wound healing (133). Fibroblasts involved in the healing process adhere particularly well to fibronectin cross-linked to fibrin by factor XIIIa transglutaminase (35). Fibronectin binds to fibrin or to fibrinogen both via its amino-terminal domain and through site(s) near the carboxyl terminus of the molecule (128, 134, 135). However, the transglutaminase-mediated cross-linking appears to occur only at the amino-terminal domain to a glutamine residue of fibronectin (119, 120, 128, 130, 136). Collagen can also be cross-linked to fibronectin by transglutaminase (84). Although the primary noncovalent binding of collagen occurs at the adjacent collagen-binding domain, the covalent cross-linking occurs only to the adjacent amino-terminal domain (119).

Several other interesting interactions are also mediated by the amino-terminal domain of fibronectin. This region also binds to the bacterium *Staphylococcus aureus* and to actin (76, 127, 131). Although the physiological consequences of these latter interactions are not yet known, binding to fibronectin might promote phagocytosis of these materials by the reticuloendothelial system as discussed earlier. DNA is also bound at multiple sites on fibronectin, but this interaction appears to be weak and is inhibited by physiological concentrations of calcium (137, 138).

Glycosaminoglycan-binding Domains

As described previously, interactions of fibronectin with heparin and heparan sulfate may play important roles in the uptake of material by macrophages or in the structural organization of the extracellular matrix (21, 30–32, 80–82, 138–143). When examined in vitro, the interactions of fibronectin and heparin appear to be complex, with at least two components of moderately high binding affinity (121).

The results of proteolytic dissection of the fibronectin molecule to identify the regions that bind to heparin affinity columns are also complex. There are two or three distinct regions of the molecule that bind to heparin (125, 126, 128–131). One binding site is located in the amino-terminal domain of the molecule (125, 128, 130, 131). Interaction of this domain with heparin can be modulated by physiological concentrations of calcium (138) and is inhibited by 0.25 M salt (130).

A second binding site is located close to the carboxyl terminus of the molecule (125, 128–131), and its binding is less sensitive to salt (130) and is insensitive to divalent cations (138). The existence of these multiple heparin-binding domains on fibronectin, and their differing sensitivities to divalent cations and salt concentrations, suggest that the interactions of fibronectin with even one ligand can be surprisingly complex and may be modulated by the local microenvironment.

Fibronectin can also bind to the glycosaminoglycan hyaluronic acid, which could affect the interactions of hyaluronic acid with cells or other extracellular matrix molecules (121, 140, 141). The binding by cellular fibronectin is kinetically complex and of moderately high affinity (121). Recent data suggest that fibronectin must exist as an aggregate in order to mediate efficient binding, because nonaggregated cellular or plasma fibronectins coupled to affinity columns bind poorly to hyaluronic acid (144). Because of this latter property, the binding region for hyaluronic acid has not yet been identified.

Disulfides and Sulfhydryls

Similar analyses of fragments of fibronectin have shown that the interchain disulfides connecting the subunits of the fibronectin dimer are very close to the carboxyl terminus (115, 118, 120, 122, 145–147). Both the amino-terminal and the collagen-binding domains are extremely rich in intrachain disulfides (113, 115, 117, 118). The amino-terminal domain contains almost 10% half cystine and probably contains 10 intrachain disulfides. These may be responsible for the compact protease-resistant structure of this domain. The intrachain disulfides of the collagen-binding domain are essential for binding to collagen (113, 115). Each subunit of fibronectin contains at least one sulfhydryl group (115, 120) located ~170,000 daltons from the amino-terminus (122) and probably a second one further towards the carboxyl terminus (122, 148).

If these sulfhydryl groups are alkylated, the binding of fibronectin into the cell surface matrix is inhibited (115, 122). It is possible that these sulfhydryls are involved in the intermolecular disulfide bonding of fibronectin either to other fibronectin molecules or to other cell surface constituents such as proteoglycans.

Structure-Function Model of Fibronectin

The current model for the structure of fibronectin based on these results postulates a series of protease-resistant structural

domains, each of which contains specific ligand-binding activities (Fig. 2). The existence of these multiple, specific domains on fibronectin can begin to explain how this molecule may act in a variety of molecular interactions. Fibronectin can be viewed as a molecule that interconnects a series of cell and matrix components to form macromolecular complexes at the cell surface and in the extracellular matrix (Fig. 3).

In addition, this model makes predictions about the requirements for certain combinations of domains for specific functions. For example, cell-cell interactions would be expected to require a multivalent molecule to enable fibronectin molecules to bind to more than one cell. Monomeric fibronectin fragments do have greatly diminished activity in such an assay (114). On the other hand, the attachment of cells to collagen would be expected to occur with even simple monomers but would require two different binding domains. As predicted, monomeric fragments of 205,000 daltons containing one cell- and one collagen-binding site are high active (114).

It will be of interest to examine the requirements for the different heparin-binding domains in the nonimmune opsonic activity of fibronectin with macrophages, in terms of which domain is required and whether the interaction can be mediated by a monomeric fragment. More complex activities of fibronectin can also be examined with these fragments. For example, the ability of fibronectin to promote migration of fibroblasts has been attributed to only the cell-binding region of the molecule (149, 150).

Role of Fibronectin's Carbohydrates

Fibronectin contains ~5% carbohydrate, consisting solely of "complex" oligosaccharides linked to asparaginyl residues. The synthesis of these oligosaccharide residues on fibronectin can be inhibited by 95-98% with tunicamycin, a relatively specific inhibitor of glycosylation (151, 153). The resultant nonglycosylated fibronectin is secreted in virtually normal quantities, suggesting that the carbohydrate moieties play no role in the

FIGURE 3 Hypothetical scheme showing fibronectin acting as a ligand, connecting the cell to the extracellular matrix. An elonaged dimeric fibronectin molecule is depicted interacting through its N-terminal domains with collagen and through other binding sites with a heparin sulfate proteoglycan (PG) and with cells. (cf. Fig. 2). One or more free sulfhydryl groups may also become involved in disulfide-bonding. The nature of the cell surface binding site is unknown—it is depicted here as an integral membrane protein (1) but it could be a protein, a glycolipid, or an assemblage of several molecules. The figure also shows one possible form of transmembrane interaction between fibronectin and actin microfilaments, involving a transmembrane "fibronectin receptor" and a molecule binding the microfilaments to the inner face of the membrane (2). Candidates for this role include vinculin, α-actinin and/or spectrin. Although the Figure is consistent with known experimental data, the details are speculative.

Table V

Plasma Versus Fibroblast Cellular Fibronectins

Action	Relative biological activity*
Cell attachment to collagen	1×
Cell spreading on plastic	1×
Uptake of particles by macrophages	1×
Morphological effects on transformed cells	3-50×‡
Hemagglutination	150-200×§

* Activity of cellular fibronectin compared to plasma fibronectin.
‡ Cellular fibronectin purified from cells by urea extraction shows 50-fold higher activity than plasma fibronectin in this assay (158). Dimeric cellular fibronectin from fibroblast culture medium is at most two- to threefold more active than plasma fibronectin (50). The differences may lie in the degree of polymerization.
§ These values are for cell surface fibronectin (158).

secretion of this glycoprotein (152). However, the rate of turnover of carbohydrate-free fibronectin is accelerated by two- to threefold, and this increased rate results in a threefold decrease in total quantities of fibronectin on the cell surface of tunicamycin-treated chick fibroblasts (152).

Isolated nonglycosylated fibronectin is unusually susceptible to various proteases (152, 154). The region of fibronectin that becomes the most susceptible to proteolysis is the collagen-binding region, which normally contains most of the carbohydrate residues of glycosylated fibronectin (154). A heparin-binding region of fibronectin that normally lacks carbohydrate has the same protease susceptibility in glycosylated or nonglycosylated fibronectin (154).

Interestingly, there is no evidence that the carbohydrate on fibronectin has any role in its known biological activities. For example, the additional branching of oligosaccharides on fibronectin that accompanies neoplastic transformation has no effect on its morphological activities (53), and even the total absence of carbohydrates after tunicamycin treatment does not alter four other biological activities of fibronectin (153). It therefore appears that the carbohydrates on this molecule function primarily to stabilize specific regions against proteolytic attack and abnormal rates of turnover; this stabilization may also be one of the major functions of carbohydrates on other glycoproteins (155).

Cellular Versus Plasma Fibronectins

Recent studies indicate that the cellular and plasma forms of fibronectin are structurally and functionally very similar, but not identical. The model shown in Fig. 2 apparently applies for both forms. Table V compares the biological activities of purified cellular and plasma fibronectins in a number of in vitro assays. The two forms of fibronectin are indistinguishable in their biological activities in assays involving cell interactions with substrates (156, 157), or in opsonic activity for macrophages (82). In contrast, the effects of these molecules on cell morphology and alignment of transformed cells and on hemagglutination are sometimes substantially different; in these assays, cellular fibronectin can be more active than plasma fibronectin (50, 157).

Biochemical studies have also revealed both similarities and differences between the two molecules. The molecules have very similar amino acid compositions, carbohydrate structures, and secondary and tertiary structures. In addition, the types and the organization of specific structural domains are indistinguishable. Nevertheless, plasma and fibroblast fibronectins have differences in pI (15), solubility (23, 24, 111), numbers of

subunits linked together by disulfide bonds (111, 158–160), and subtle differences in the apparent size of specific domains (113, 131). Any of these differences might be related to the biological differences. An interesting finding in this regard is that the regions of apparent difference between the two forms can be mapped to the interior of the molecules, rather than to an end (131, 161). This finding appears to rule out the previous most popular hypothesis that the two forms are related by simple proteolytic processing of one form to the other. Monoclonal antibodies provide independent evidence that the two forms are distinct, because monoclonal antibodies have been found that bind preferentially to cellular as compared with plasma fibronectin (161, 162). One of these distinguishing monoclonals binds a determinant located near to the carboxy-terminal end but internal to the interchain disulfide bonds and its binding does not appear to require the presence of carbohydrate (161). This suggests the existence of differences in primary sequence.

These studies indicate that although the two forms of fibronectin are very similar, they are structurally and functionally distinct. It will be of considerable interest to determine whether the two forms are the product of two or more distinct genes, or whether they are encoded by a single gene that produces an RNA that is differentially processed to produce mRNA's encoding either cellular or plasma fibronectins.

CONCLUSIONS AND FUTURE PROSPECTS

Analysis of the structure of fibronectins reveals a modular structure that appears well suited for functioning as an adhesive ligand-like molecule. Fig. 3 shows one current view of fibronectin in the role of a cell-matrix ligand and also depicts the possible relationship with intracellular microfilaments. Obviously, several features of this model remain uncertain. However, the general picture of a molecule with binding sites specific for some cell surface molecule(s) connected to other binding sites specific for various extracellular moieties is well-founded on experimental data. Furthermore, some form of relationship with intracellular microfilaments is in accord with current data (10, 38–48), although the molecular basis for the transmembrane relationship remains unknown.

This picture of an involvement of fibronectin in a connection between the cytoskeleton and the extracellular matrix, and in cellular interactions with this matrix, suggests plausible and testable hypotheses to explain the roles played by fibronectins in the various cellular properties discussed earlier (Table IV). The challenge now is to test these hypotheses and resolve the unanswered questions.

Although much is known about the structure (Fig. 2), not all the interactions of fibronectin (Table III) can yet be assigned to specific locations within the molecule, and the details of many of the interactions remain to be analyzed. Further work along the lines discussed earlier should provide much of this information. Detailed structural studies (primary sequence, biophysical measurements) on the individual domains should be available in the near future. Acquisition of primary sequence data will be greatly aided by nucleic acid cloning studies now in progress. Detailed protein structural and nucleic acid analyses will also provide further insight into the nature of the differences between plasma and cellular fibronectins and the possibility of multiple forms of fibronectin.

The modular structure of fibronectin lends itself well to the development of antibodies specific for different functional regions. Several monoclonal antibodies are already available (132, 161, 162), as well as some domain-specific polyclonal

antisera (112, 163, 164). In the future, these reagents should be useful for investigating which local domains and binding sites function in which of the more complex biological functions (Table IV). The combination of a detailed analysis of the structure of fibronectins with the development of antibodies able to interfere with specific functions should provide a clear picture of the structure-function relationships of these complex proteins.

Two important properties of fibronectin that remain enigmatic are its ability to form fibrils and its interaction with cells. Analysis by chemical cross-linking, antibodies, and other techniques should allow identification of the cell surface binding site(s) and of the arrangement of fibronectin and other molecules in the fibrils.

The suggested roles of fibronectins in complex biological phenomena such as cell migration, cellular differentiation, hemostasis and thrombosis, reticuloendothelial clearance, and cancer all require much more extensive investigation. Studies of these phenomena in vivo will be contingent upon progress on the biochemical, immunological, and cell biological analyses of fibronectins. Furthermore, because fibronectins undoubtedly interact in vivo with other molecules (collagens, proteoglycans), these other constituents will have to be studied in parallel. It also seems clear that several other proteins of a type similar to fibronectins also function as cell-matrix ligands (eg, laminin, chondronectin, von Willebrands factor, thrombospondin) and this list is likely to grow rapidly. The complex interaction among these various molecules are likely to provide a fertile field for research in the next few years, as they have in the last several.

REFERENCES

1. Hynes, R. O. 1976. Cell surface proteins and malignant transformation. Biochim. Biophys. Acta. 458:73–107.
2. Yamada, K. M., and K. Olden. 1978. Fibronectins: adhesive glycoproteins of cell surface and blood. Nature (Lond.) 275:179–184.
3. Vaheri, A., and D. F. Mosher. 1978. High molecular weight, cell surface-associated glycoprotein (fibronectin) lost in malignant transformation. Biochim. Biophys. Acta. 516:1–25.
4. Mosher, D. F. 1980. Fibronectin. Prog. Hemostasis Thromb. 5:111–151.
5. Saba, T. M., and E. Jaffe. 1980. Plasma fibronectin (opsonic glycoprotein): its synthesis by endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am. J. Med. 68:577–594.
6. Mosesson, M. W., and D. L. Amrani. 1980. The structure and biological activities of plasma fibronectin. Blood. 56:145–158.
7. Pearlstein, E., L. I. Gold, and A. Garcia-Pardo. 1980. Fibronectin: a review of its structure and biological activity. Mol. Cell. Biochem. 29:103–128.
8. Wartiovaara, J., and A. Vaheri. 1980. Fibronectin and early mammalian embryogenesis. Dev. Mamm. 4:233–266.
9. Ruoslahti, E., E. Engvall, and E. G. Hayman. 1981. Fibronectin: current concepts of its structure and function. Coll. Res. 1:95–128.
10. Hynes, R. O. 1981. Relationships between fibronectin and the cytoskeleton, in Cell Surf. Rev. 7:97–136.
11. Hynes, R. O. 1981. Fibronectin and its relation to cell structure and behavior. In Cell Biology of the Extracellular Matrix. E. D. Hay, editor. Plenum Publishing Corp., New York. 295–333.
12. Yamada, K. M. 1982. Biochemistry of fibronectin. In The Glycoconjugates, Vol. III. M. I. Horowitz, editor. Academic Press, New York.
13. Akiyama, S. K., and K. M. Yamada. 1982. Fibronectin in Disease. In Connective Tissues and Diseases of Connective Tissues. R. Fleischmajer and B. Wagner, editors. Williams and Wilkins Co., Baltimore.
14. Voss, B., S. Allah, J. Rauterberg, K. Ullrich, V. Gieselmann, and K. Von Figura. 1979. Primary cultures of rat hepatocytes synthesize fibronectin. Biochem. Biophys. Res. Commun. 90:1348–1354.
15. Reference deleted in proof.
16. Birdwell, C. R., D. Gospodarowicz, and G. L. Nicolson. 1978. Identification, localization and role of fibronectin in cultured bovine endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 75:3273–3277.
17. Macarak, E. J., E. Kirby, T. Kirk, and N. A. Kefalides. 1978. Synthesis of cold-insoluble globulin by cultured calf endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 75:2621–2625.
18. Jaffe, E. A., and D. F. Mosher. 1978. Synthesis of fibronectin by cultured human endothelial cells. J. Exp. Med. 147:1779–1791.
19. Alitalo, K., T. Hovi, and A. Vaheri. 1980. Fibronectin is produced by human macrophages. J. Exp. Med. 151:602–613.
20. Johansson, S., K. Rubin, M. Hook, T. Ahlgren, and R. Seljelin. 1979. In vitro biosynthesis of cold-insoluble globulin (fibronectin) by mouse peritoneal macrophages. FEBS (Fed. Eur. Biochem. Soc.) Lett. 105:313–316.
21. van de Water III, L., S. Schroeder, E. B. Crenshaw, and R. O. Hynes. 1981. Phagocytosis of gelatin-latex particles by a murine macrophage line is dependent on fibronectin and heparin. J. Cell Biol. 90:32–39.

22. Villiger, B., D. G. Kelley, W. Engleman, C. Kuhn, and J. A. McDonald. 1981. Human alveolar macrophage fibronectin-synthesis, secretion, and ultrastructural localization during gelatin-coated latex particle binding. *J. Cell Biol.* 90:711–720.

23. Alexander, S. S., G. Colonna, K. M. Yamada, I. Pastan, and H. Edelhoch. 1978. Molecular properties of a major cell surface protein from chick embryo fibroblasts. *J. Biol. Chem.* 253:5820–5824.

24. Alexander, S. S., G. Colonna, and H. Edelhoch. 1979. The structure and stability of human plasma cold-insoluble globulin. *J. Biol. Chem.* 254:1501–1505.

25. Engel, J., E. Odermatt, A. Engel, J. A. Madri, H. Furthmayr, H. Rohde, and R. Timpl. 1981. Shapes, domain organization and flexibility of laminin and fibronectin, two multifunctional proteins of the extracellular matrix. *J. Mol. Biol.* 150:97–120.

26. Erickson, H. P., N. Carrell, and J. McDonagh. 1981. Fibronectin molecule visualized in electron microscopy: a long, thin, flexible strand. *J. Cell Biol.* 91:673–678.

27. Koteliansky, V. E., M. A. Glukhova, M. V. Bejanian, V. N. Smirnov, V. V. Filimonov, O. M. Zalite, and S. Y. Venyaminov. 1981. A study of the structure of fibronectin. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 119:619–624.

28. Vaheri, A., M. Kurkinen, V. P. Lehto, E. Linder, and R. Timpl. 1978. Codistribution of pericellular matrix proteins in cultured fibroblasts and loss in transformation: fibronectin and procollagen. *Proc. Natl. Acad. Sci. U. S. A.* 75:4944–4948.

29. Hedman, K., M. Kurkinen, K. Alitalo, A. Vaheri, S. Johannson, and M. Hook. 1979. Isolation of the pericellular matrix of human fibroblasts cultures. *J. Cell Biol.* 81:83–91.

30. Perkins, M. E., T. H. Ji, and R. O. Hynes. 1979. Crosslinking of fibronectin to sulfated proteoglycans at the cell surface. *Cell.* 16:941–953.

31. Culp, L. A., B. A. Murray, and B. J. Rollins. 1980. Fibronectin and proteoglycans as determinants of cell-substratum adhesion. *In* Tumor Cell Surfaces and Malignancy. R. O. Hynes and C. F. Fox, editors. Alan R. Liss, Inc. New York. 281–307.

32. Hedman, K., S. Johannson, T. Vartio, L. Kjellen, A. Vaheri, and M. Hook. 1982. Structure of the pericellular matrix: association of heparin and chondroitin sulfates with fibronectin-collagen fibers. *Cell.* 28:663–671.

33. Grinnell, F. 1978. Cellular adhesiveness and extracellular substrata. *Int. Rev. Cytol.* 53:65–144.

34. Kleinman, H. K., R. J. Klebe, and G. R. Martin. 1981. Role of collagenous matrices in the adhesion and growth of cells. *J. Cell Biol.* 88:473–485.

35. Grinnell, F., M. Feld, and D. Minter. 1980. Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin). *Cell.* 19:517–525.

36. Culp, L. A. 1978. Biochemical determinants of cell adhesion. *Curr. Top. Membr. Transp.* 11:327–396.

37. Yamada, K. M., S. S. Yamada, and I. Pastan. 1976. Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. *Proc. Natl. Acad. Sci. U. S. A.* 73:1217–1221.

38. Ali, I. U., V. M. Mautner, R. P. Lanza, and R. O. Hynes. 1977. Restoration of normal morphology, adhesion and cytoskeleton in transformed cells by addition of a transformation-sensitive surface protein. *Cell.* 11:115–126.

39. Willingham, M. C., K. M. Yamada, S. S. Yamada, J. Pouyssegur, and I. Pastan. 1977. Microfilament bundles and cell shape are related to adhesiveness to substratum and are dissociable from growth control in cultured fibroblasts. *Cell.* 10:375–380.

40. Hynes, R. O., and A. T. Destree. 1978. Relationships between fibronectin (LETS protein) and actin. *Cell.* 15:875–886.

41. Heggeness, M. H., J. F. Ash, and S. J. Singer. 1978. Transmembrane linkage of fibronectin to intracellular actin-containing filaments in cultured human fibroblasts. *Ann. N. Y. Acad. Sci.* 312:414–417.

42. Singer, I. I. 1979. The fibronexus: a transmembrane association of fibronectin-containing fibers and bundles of 5nm microfilaments in hamster and human fibroblasts. *Cell.* 16:675–685.

43. Burridge, K., and J. Feramisco. 1980. Microinjection and localization of a 130k protein in living fibroblasts: a relationship to actin and fibronectin. *Cell.* 19:587–595.

44. Singer, I. I., and P. R. Paradiso. 1981. A transmembrane relationship between fibronectin and vinculin (130k protein): serum modulation in normal and transformed hamster fibroblasts. *Cell.* 24:481–492.

45. Chen, W. T., and S. J. Singer. 1980. Fibronectin is not present in the focal adhesions formed between normal cultured fibroblasts and their substrata. *Proc. Natl. Acad. Sci. U. S. A.* 77:7318–7322.

46. Singer, I. I. 1982. Association of fibronectin and vinculin with focal contacts and stress fibers in stationary hamster fibroblasts. *J. Cell Biol.* 92:398–408.

47. Hynes, R. O., A. T. Destree, and D. D. Wagner. 1982. Relationships between microfilaments, cell-substratum adhesion and fibronectin. *Cold Spring Harbor Symp. Quant. Biol.* 46:659–670.

48. Hynes, R. O. 1982. Phosphorylation of vinculin by pp60^{src}: what might it mean? *Cell.* 28:437–438.

49. Olden, K., and K. M. Yamada. 1977. Mechanism of the decrease in the major cell surface protein of chick embryo fibroblasts after transformation. *Cell.* 11:957–969.

50. Hynes, R. O., I. U. Ali, A. T. Destree, V. Mautner, M. E. Perkins, D. R. Senger, D. D. Wagner, and K. K. Smith. 1978. A large glycoprotein lost from the surfaces of transformed cells. *Ann. N. Y. Acad. Sci.* 312:317–342.

51. Vaheri, A., and E. Ruoslahti. 1975. Fibroblast surface antigen produced but not retained by virus-transformed human cells. *J. Exp. Med.* 142:530–538.

52. Hayman, E. G., E. Engvall, and E. Ruoslahti. 1981. Concomitant loss of cell surface fibronectin and laminin from transformed rat kidney cells. *J. Cell Biol.* 88:352–357.

53. Wagner, D. D., R. Ivatt, A. T. Destree, and R. O. Hynes. 1981. Similarities and differences between the fibronectins of normal and transformed hamster cells. *J. Biol. Chem.* 256:11708–11715.

54. Hynes, R. O., J. A. Wyke, J. M. Bye, K. C. Humphryes, and E. S. Pearlstein. 1975. Are proteases involved in altering cell surface proteins during viral transformation? *In* Proteases and Biological Control. E. Reich, E. Shaw, and D. B. Rifkin, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 931–944.

55. Chen, L. B., P. H. Gallimore, and J. K. McDougall. 1976. Correlation between tumor induction and the large external transformation sensitive protein on the cell surface. *Proc. Natl. Acad. Sci. U. S. A.* 73:3570–3574.

56. Gallimore, P. H., J. K. McDougall, and J. B. Chen. 1977. In vitro traits of adenovirus-transformed cell lines and their relevance to tumorigenicity in nude mice. *Cell.* 10:669–678.

57. Kahn, P., and S. I. Shin. 1979. Cellular tumorigenicity in nude mice. Test of associations among loss of cell-surface fibronectin, anchorage independence, and tumor-forming ability. *J. Cell Biol.* 82:1–16.

58. Der, C. J., and E. J. Stanbridge. 1978. Lack of correlation between the decreased expression of cell surface LETS protein and tumorigenicity in human cell hybrids. *Cell.* 15:1241–1251.

59. Gallimore, P. H., J. K. McDougall, and L. B. Chen. 1979. Malignant behavior of three adenovirus-2-transformed brain cell lines and their methyl cellulose-selected sub-clones. *Int. J. Cancer.* 24:477–484.

60. Smith, H. S., J. L. Riggs, and M. W. Mosesson. 1979. Production of fibronectin (LETS protein) by human epithelial cells in culture. *Cancer Res.* 39:4138–4145.

61. Labat-Robert, J., P. Birembaut, J. J. Adnet, F. Mercantini, and L. Robert. 1980. Loss of fibronectin in human breast cancer. *Cell Biol. Int. Rep.* 4:608–616.

62. Ali, I. U., and R. O. Hynes. 1978. Effects of LETS glycoprotein on cell motility. *Cell.* 14:439–446.

63. Yamada, K. M., K. Olden, and I. Pastan. 1978. Transformation-sensitive cell surface protein: isolation, characterization, and role in cellular morphology and adhesion. *Ann. N. Y. Acad. Sci.* 312:256–277.

64. Gauss-Muller, V., H. K. Kleinman, G. R. Martin, and E. Schiffmann. 1980. Role of attachment and attractants in fibroblast chemotaxis. *J. Lab. Clin. Med.* 96:1071–1080.

65. Greenberg, J. H., S. Seppä, H. Seppä, and A. T. Hewitt. 1981. Role of collagen and fibronectin in neural crest cell adhesion and migration. *Dev. Biol.* 87:259–266.

66. Critchley, D. R., M. A. England, J. Wakely, and R. O. Hynes. 1979. Distribution of fibronectin in the ectoderm of gastrulating chick embryos. *Nature (Lond.).* 280:498–500.

67. Newgreen, D., and J. P. Thiery. 1980. Fibronectin in early avian embryos: synthesis and distribution along the migration pathways of neural crest cells. *Cell Tissue Res.* 211:269–291.

68. Mayer, B. W., E. D. Hay, and R. O. Hynes. 1981. Immunocytochemical localization of fibronectin in embryonic chick trunk and area vasculosa. *Dev. Biol.* 82:267–286.

69. Duband, J. L., and J. P. Thiery. 1982. Distribution of fibronectin in the early phases of avian cephalic neural crest cell migration. *Dev. Biol.* In press.

70. Thiery, J. P., J. L. Duband, and A. Delouvee. 1982. Pathways and mechanisms of avian trunk neural crest cell migration and localization. *Dev. Biol.* In press.

71. Heasman, J., R. O. Hynes, A. P. Swan, V. Thomas, and C. C. Wylie. 1981. Primordial germ cells of Xenopus embryos: the role of fibronectin in their adhesion during migration. *Cell.* 27:437–447.

72. Spiegel, E., M. Burger, and M. Spiegel. 1980. Fibronectin in the developing sea urchin embryo. *J. Cell Biol.* 87:309–313.

73. Katow, H., K. M. Yamada, and M. Solursh. 1982. Occurrence of fibronectin on the primary mesenchyme cell surface during migration in the sea urchin embryo. *Differentiation.* 28:120–124.

74. Akers, R. M., D. F. Mosher, and J. E. Lilien. 1981. Promotion of retinal neurite outgrowth by substratum-bound fibronectin. *Dev. Biol.* 86:179–188.

75. Kuusela, P. 1978. Fibronectin binds to *Staphylococcus aureus. Nature (Lond.).* 276:718–720.

76. Mosher, D. F., and R. A. Proctor. 1980. Binding and factor XIIIa-mediated crosslinking of a 27-kilodalton fragment of fibronectin to *Staphylococcus aureus. Science (Wash. D. C.).* 209:927–929.

77. Menzel, E. J., J. S. Smolen, L. Liotta, and K. B. M. Reid. 1981. Interaction of fibronectin with Clq and its collagen-like fragment (CLF). *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 129:188–192.

78. Pearlstein, E., J. Sorvillo, and I. Gigli. 1982. The interaction of human plasma fibronectin with a subunit of the first component of complement, Clq. *J. Immunol.* 128:2036–2039.

79. Bing, D. H., S. Almeda, H. Isliker, J. Lahav, and R. O. Hynes. 1982. Fibronectin binds to the Clq component of complement. *Proc. Natl. Acad. Sci. U. S. A.* 79:4198–4201.

80. Molnar, J., F. B. Gelder, M. Z. Lai, G. E. Siefring, R. B. Credo, and L. Lorand. 1979. Purification of opsonically active human and rat cold-insoluble globulin (plasma fibronectin). *Biochemistry.* 18:3909–3916.

81. Gudewicz, P. W., J. Molnar, M. Z. Lai, D. W. Beezhold, G. E. Siefring, R. B. Credo, and L. Lorand. 1980. Fibronectin-mediated uptake of gelatin-coated latex particles by peritoneal macrophages. *J. Cell Biol.* 87:427–433.

82. Marquette, D., J. Molnar, K. M. Yamada, D. Schlesinger, S. Darby, and P. Van Alten. 1981. Phagocytosis-promoting activity of avian plasma and fibroblastic cell surface fibronectin. *Mol. Cell Biochem.* 36:147–155.

83. Mosher, D. F. 1976. Action of fibrin-stabilizing factor on cold-insoluble globulin and α2-macroglobulin in clotting plasma. *J. Biol. Chem.* 251:1639–1645.

84. Mosher, D. F., P. E. Schad, H. D. Kleinman. 1979. Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. *J. Clin. Invest.* 64:781–787.

85. Plow, E. F., C. Birdwell, and M. H. Ginsberg. 1979. Identification and quantitation of platelet associated fibronectin antigen. *J. Clin. Invest.* 63:540–543.

86. Zucker, M. B., M. W. Mosesson, M. J. Broekman, and K. L. Kaplan. 1979. Release of platelet fibronectin (cold-insoluble globulin) from alpha granules induced by thrombin or collagen; lack of requirement for plasma fibronectin in ADP-induced platelet aggregation. *Blood.* 54:8–12.

87. Ginsberg, M. H., R. G. Painter, J. Forsyth, C. Birdwell, and E. F. Plow. 1980. Thrombin increases expression of fibronectin antigen on the platelet surface. *Proc. Natl. Acad. Sci. U. S. A.* 77:1049–1053.

88. Lahav, J., and R. O. Hynes. 1981. Involvement of fibronectin, von Willebrand factor and fibrinogen in platelet interaction with solid substrata. *J. Supramol. Struct. Cell. Biochem.* 17:299–311.

89. Plow, E. F., and M. H. Ginsberg. 1981. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. *J. Biol. Chem.* 256:9477–9482.

90. Hoyer, L. W. 1981. The factor VIII complex: structure and function. *Blood.* 58:1–13.

91. Sakariassen, K. S., P. A. Bolhuis, and J. J. Sixma. 1979. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII von Willebrand factor bound to the subendothelium. *Nature (Lond.).* 279:636–638.

92. Baenziger, N. L., G. N. Brodie, and P. W. Majerus. 1972. Isolation and properties of a thrombin-sensitive protein of human platelets. *J. Biol. Chem.* 247:2723–2731.

93. Lawler, J. W., H. S. Slayter, and J. E. Coligan. 1978. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. *J. Biol. Chem.* 253:8609–8616.

94. McPherson, J., H. Sage, and P. Bornstein. 1981. Isolation and characterization of a glycoprotein secreted by aortic endothelial cells in culture: apparent identity with platelet thrombospondin. *J. Biol. Chem.* 256:11330–11336.

95. Grinnell, F., M. Feld, and W. Snell. 1979. The influence of cold insoluble globulin on platelet morphological response to substrata. *Cell Biol. Int. Rep.* 3:585–592.

96. Koteliansky, V. E., V. L. Leytin, D. D. Sviridov, V. S. Repin, and V. N. Smirnov. 1981. Human plasma fibronectin promotes the adhesion and spreading of platelets on surfaces coated with fibrillar collagen. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 123:59–62.

97. Lahav, J., M. A. Schwartz, and R. O. Hynes. 1982. Analysis of platelet adhesion using a radioactive chemical crosslinking reagent: interaction of thrombospondin with fibronectin and collagen. *Cell.* In press.

98. Gartner, T. K., D. C. Williams, F. C. Minion, and D. R. Phillips. 1978. Thrombin-induced platelet aggregation is mediated by a platelet plasma membrane-bound lectin. *Science (Wash. D. C.).* 200:1281–1283.

99. Jaffe, E. A., L. L. K. Leung, R. L. Nachman, R. I. Levin, and D. F. Mosher. 1982. Thrombospondin is the endogenous lectin of human platelets. *Nature (Wash. D. C.).* 295:246–248.

100. Chen, L. B. 1977. Alteration in cell surface LETS protein during myogenesis. *Cell.* 10:393–400.

101. Podleski, T. R., I. Greenberg, J. Schlessinger, and K. M. Yamada. 1979. Fibronectin delays the fusion of L6 myoblasts. *Exp. Cell Res.* 122:317–326.

102. West, C. M., R. Lanza, J. Rosenbloom, M. Lowe, H. Holtzer, and N. Avdalovic. 1979. Fibronectin alters the phenotypic properties of cultured chick embryo chondroblasts. *Cell.* 17:491–501.

103. Pennypacker, J. P., J. R. Hassell, K. M. Yamada, and R. M. Pratt. 1979. The influence of an adhesive cell surface protein on chondrogenic expression *in vitro. Exp. Cell Res.* 121:411–415.

104. Dessau, W., J. Sasse, R. Timpl, F. Jilek, and K. von der Mark. 1978. Synthesis and extracellular deposition of fibronectin in chondrocyte cultures. *J. Cell Biol.* 79:342–355.

105. Dessau, W., H. von der Mark, K. von der Mark, and S. Fischer. 1980. Changes in the patterns of collagens and fibronectin during limb-bud chondrogenesis. *J. Embryol. Exp. Morphol.* 57:51–60.

106. Silver, M. H., J. M. Foidart, R. M. Pratt. 1981. Distribution of fibronectin and collagen during mouse limb and palate development. *Differentiation.* 18:141–149.

107. Chiquet, M., H. M. Eppenberger, and D. C. Turner. 1981. Muscle morphogenesis: evidence for an organizing function of exogenous fibronectin. *Dev. Biol.* 88:220–235.

108. Tomasek, J. J., J. E. Mazurkiewicz, and S. A. Newman. 1982. Nonuniform distribution of fibronectin during avian limb development. *Dev. Biol.* 90:118–126.

109. Sieber-Blum, M., F. Sieber, and K. M. Yamada. 1981. Cellular fibronectin promotes adrenergic differentiation of quail neural crest cells in vitro. *Exp. Cell Res.* 133:285–292.

110. Loring, J., B. Glimelius, and J. A. Weston. 1982. Extracellular matrix materials influence quail neural crest cell differentiation in vitro. *Dev. Biol.* 90:165–174.

111. Yamada, K. M., D. H. Schlesinger, D. W. Kennedy, and I. Pastan. 1977. Characterization of a major fibroblast cell surface glycoprotein. *Biochemistry.* 16:5552–5559.

112. Ruoslahti, E., E. G. Hayman, P. Kuusela, J. E. Shively, and E. Engvall. 1979. Isolation of a tryptic fragment containing the collagen-binding site of plasma fibronectin. *J. Biol. Chem.* 254:6054–6059.

113. Balian, G., E. M. Click, E. Crouch, J. M. Davidson, and P. Bornstein. 1979. Isolation of a collagen-binding fragment from fibronectin and cold-insoluble globulin. *J. Biol. Chem.* 254:1429–1432.

114. Hahn, L. H. E., and K. M. Yamada. 1979. Identification and isolation of a collagen-binding fragment of the adhesive glycoprotein fibronectin. *Proc. Natl. Acad. Sci. U. S. A.* 76:1160–1163.

115. Wagner, D. D., R. O. Hynes. 1979. Domain structure of fibronectin and its relation to function; disulfides and sulfhydryl groups. *J. Biol. Chem.* 254:6746–6754.

116. Hahn, L. H. E., and K. M. Yamada. 1979. Isolation and biological characterization of active fragments of the adhesive glycoprotein fibronectin. *Cell.* 18:1043–1051.

117. Gold, L. I., A. Garcia-Pardo, B. Frangione, E. C. Franklin, and E. Pearlstein. 1979. Subtilisin and cyanogen bromide cleavage products of fibronectin that retain gelatin-binding activity. *Proc. Natl. Acad. Sci. U. S. A.* 76:4803–4807.

118. Furie, M., and D. B. Rifkin. 1980. Proteolytically derived fragments of human plasma fibronectin and their localization within the intact molecule. *J. Biol. Chem.* 255:3134–3140.

119. Mosher, D. F., P. E. Schad, and J. M. Vann. 1980. Cross-linking of collagen and fibronectin by factor XIIIa: localization of participating glutaminyl residues to a tryptic fragment of fibronectin. *J. Biol. Chem.* 255:1181–1188.

120. McDonald, J. A., and D. G. Kelley. 1980. Degradation of fibronectin by human leukocyte elastase. *J. Biol. Chem.* 255:8848–8858.

121. Yamada, K. M., D. W. Kennedy, Kimata, K. and R. M. Pratt. 1980. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. *J. Biol. Chem.* 255:6055–6063.

122. Wagner, D. D., and R. O. Hynes. 1980. Topological arrangement of the major structural features of fibronectin. *J. Biol. Chem.* 255:4304–4312.

123. Balian, G., E. M. Click, and P. Bornstein. 1980. Location of a collagen-binding domain in fibronectin. *J. Biol. Chem.* 255:3234–3236.

124. Furie, M. B., A. B. Frey, and D. B. Rifkin. 1980. Location of a gelatin-binding region of human plasma fibronectin. *J. Biol. Chem.* 255:4391–4394.

125. Sekiguchi, K., and S. I. Hakomori. 1980. Functional domain structure of fibronectin. *Proc. Natl. Acad. Sci. U. S. A.* 77:2661–2665.

126. Hayashi, M., D. H. Schlesinger, D. W. Kennedy, and K. M. Yamada. 1980. Isolation and characterization of a heparin-binding domain of cellular fibronectin. *J. Biol. Chem.* 255:10017–10020.

127. Keski-Oja, J., and K. M. Yamada. 1981. Isolation of an actin-binding fragment of fibronectin. *Biochem. J.* 193:615–620.

128. Sekiguchi, K., M. Fukuda, and S. Hakomori. 1981. Domain structure of hamster plasma fibronectin: isolation and characterization of four functionally distinct domains and their unequal distribution between two subunit polypeptides. *J. Biol. Chem.* 256:6452–6462.

129. Ruoslahti, E., E. G. Hayman, E. Engvall, W. C. Cothran, and W. T. Butler. 1981. Alignment of biologically active domains in the fibronectin molecule. *J. Biol. Chem.* 256:7277–7281.

130. Richter, H., M. Seidl, and H. Hormann. 1981. Location of heparin-binding sites of fibronectin: detection of a hitherto unrecognized transamidase sensitive site. *Hoppe-Seyler's Z. Physiol. Chem.* 362:399–408.

131. Hayashi, M., and K. M. Yamada. 1981. Differences in domain structures between plasma and cellular fibronectins. *J. Biol. Chem.* 256:11292–11300.

132. Pierschbacher, M. D., E. G. Hayman, and E. Ruoslahti. 1981. Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. *Cell.* 26:259–267.

133. Grinnell, F., R. E. Billingham, and L. Burgess. 1981. Distribution of fibronectin during wound healing in vivo. *J. Invest. Dermatol.* 75:181–189.

134. Hormann, H., and M. Seidl. 1980. Affinity chromatography on immobilized fibrin monomer III; the fibrin affinity center of fibronectin. *Hoppe-Seyler's Z. Physiol. Chem.* 361:1449–1452.

135. Hayashi, M., and K. M. Yamada. 1983. Domain structure of the carboxyl terminal half of human plasma fibronectin. *J. Biol. Chem.* In press.

136. Jilek, F., and H. Hormann. 1977. Cold insoluble globulin. III. Cyanogen bromide and plasminolysis fragments containing a label introduced by transamidation. *Hoppe-Seyler's Z. Physiol. Chem.* 358:1165–1168.

137. Zardi, L., A. Siri, B. Carnemolla, L. Santi, W. D. Gardner, and S. O. Hoch. 1979. Fibronectin: a chromatin-associated protein? *Cell.* 18:649–657.

138. Hayashi, M., and K. M. Yamada. 1982. Divalent cation modulation of fibronectin binding to heparin and DNA. *J. Biol. Chem.* 257:5263–5267.

139. Stathakis, N. E., and M. W. Mosesson. 1977. Interactions among heparin, cold-insoluble globulin, and fibrinogen in formation of the heparin-precipitable fraction of plasma. *J. Clin. Invest.* 60:855–865.

140. Jilek, F., and H. Hormann. 1979. Fibronectin (cold insoluble globulin) VI influence of heparin and hyaluronic acid on the binding of native collagen. *Hoppe-Seyler's Z. Physiol. Chem.* 360:597–603.

141. Hormann, H., and V. Jelinic. 1981. Regulation by heparin and hyaluronic acid of the fibronectin-dependent association of collagen, type III, with macrophages. *Hoppe-Seyler's Z. Physiol. Chem.* 362:87–94.

142. Ruoslahti, E., and E. Engvall. 1980. Complexing of fibronectin, glycosaminoglycans and collagen. *Biochim. Biophys. Acta.* 631:350–358.

143. Johansson, S., and M. Hook. 1980. Heparin enhances the rate of binding of fibronectin to collagen. *Biochim. J.* 187:521–524.

144. Laterra, J., and L. A. Culp. 1982. Differences in hyaluronate binding to plasma and cell surface fibronectins: requirement for aggregation. *J. Biol. Chem.* 257:719–726.

145. Jilek, F., and H. Hormann. 1977. Cold-insoluble globulin II. Plasminolysis of cold-insoluble globulin. *Hoppe-Seyler's Z. Physiol. Chem.* 358:133–136.

146. Chen, A. B., D. L. Amrani, and M. W. Mosesson. 1977. Heterogeneity of the cold-insoluble globulin of human plasma (CIg), a circulating cell surface protein. *Biochim. Biophys. Acta.* 493:310–322.

147. Fukuda, M., and S. Hakomori. 1979. Proteolytic and chemical fragmentation of galactoprotein a, a major transformation-sensitive glycoprotein released from hamster embryo fibroblasts. *J. Biol. Chem.* 254:5442–5449.

148. Smith, D. E., D. F. Mosher, R. B. Johnson, and L. T. Furcht. 1982. Immunological identification of two sulfhydryl-containing fragments of human plasma fibronectin. *J. Biol. Chem.* 257:5831–5838.

149. Postlethwaite, A. E., J. Keski-Oja, G. Balian, and A. H. Kang. 1981. Induction of fibroblast chemotaxis by fibronectin: localization of the chemotactic region to a 140,000 molecular weight non-gelatin-binding fragment. *J. Exp. Med.* 153:494–499.

150. Seppä, H. E. J., K. M. Yamada, S. T. Seppä, M. H. Silver, H. K. Kleinman, and E. Schiffmann. 1981. The cell-binding fragment of fibronectin is chemotactic for fibroblasts. *Cell Biol. Int. Rep.* 5:813–819.

151. Duksin, D., and P. Bornstein. 1977. Changes in surface properties of normal and transformed cells caused by tunicamycin, an inhibitor of protein glycosylation. *Proc. Natl. Acad. Sci. U. S. A.* 74:3433–3437.

152. Olden, K., R. M. Pratt, and K. M. Yamada. 1978. Role of carbohydrates in protein secretion and turnover: effects of tunicamycin on the major cell surface glycoprotein of chick embryo fibroblasts. *Cell.* 13:461–473.

153. Olden, K., R. M. Pratt, and K. M. Yamada. 1979. Role of carbohydrate in biological function of the adhesive glycoprotein fibronectin. *Proc. Natl. Acad. Sci. U. S. A.* 76:3343–3347.

154. Bernard, B. A., K. M. Yamada, and K. Olden. 1982. Carbohydrates selectively protect a specific domain of fibronectin against proteases. *J. Biol. Chem.* 257:8549–8554.

155. Yamada, K. M., and K. Olden. 1982. Actions of tunicamycin on vertebrate cells. *In* Tunicamycin. G. Tamura, editor. Japan Scientific Societies Press, Tokyo. 119–144.

156. Pena, S. D. J., and R. G. Hughes. 1978. Fibroblast to substratum contacts mediated by the different forms of fibronectin. *Cell Biol. Int. Rep.* 2:339–344.

157. Yamada, K. M., and D. W. Kennedy. 1979. Fibroblast cellular and plasma fibronectins are similar but not identical. *J. Cell Biol.* 80:492–498.

158. Hynes, R. O., and A. T. Destree. 1977. Extensive disulfide bonding at the mammalian cell surface. *Proc. Natl. Acad. Sci. U. S. A.* 74:2855–2859.

159. Keski-Oja, T., D. F. Mosher, and A. Vaheri. 1977. Dimeric character of fibronectin, a major cell surface-associated glycoprotein. *Biochem. Biophys. Res. Commun.* 74:699–706.

160. McConnell, M. R., P. M. Blumberg, and P. W. Rostow. 1978. Dimeric and high molecular weight forms of the large external transformation-sensitive protein on the surface of chick embryo fibroblasts. *J. Biol. Chem.* 253:7522–7530.

161. Atherton, B. T., and R. O. Hynes. 1981. A difference between plasma and cellular fibronectins located with monoclonal antibodies. *Cell.* 25:133–141.

162. Noonan, K. D., N. E. Noonan, and K. Yamada. 1981. Monoclonal antibodies directed against fragments of fibronectin. *J. Supramol. Struct. Cell. Biochem. Suppl.* 5:302.

163. McDonald, J. A., T. J. Broekelmann, D. G. Kelley, and B. Villiger. 1981. Gelatin-binding domain-specific anti-human plasma fibronectin Fab inhibits fibronectin-mediated gelatin binding but not cell spreading. *J. Biol. Chem.* 256:5583–5587.

164. McDonald, J. A., D. G. Kelley, and T. J. Broekelmann. 1982. Role of fibronectin in collagen deposition: Fab to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix. *J. Cell Biol.* 92:485–492.

165. Kleinman, H. K., G. R. Martin, and P. H. Fishman. 1979. Ganglioside inhibition of fibronectin-mediated cell adhesion to collagen. *Proc. Natl. Acad. Sci. U. S. A.* 76:3367–3371.

166. Yamada, K. M., D. W. Kennedy, G. R. Grotendorst, and T. Momoi. 1981. Glycolipids: receptors for fibronectin? *J. Cell Physiol.* 109:343–351.

167. Emmerling, M. R., C. D. Johnson, D. F. Mosher, B. H. Lipton, and J. E. Lilien. 1981. Cross-linking and binding of fibronectin with asymmetric acetylcholinesterase. *Biochemistry.* 20:3242–3247.